Geron (NASDAQ:GERN) Posts Earnings Results, Hits Estimates

Geron (NASDAQ:GERN) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04), Zacks reports. The company had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%.

Geron Stock Up 1.6 %

GERN stock opened at $1.64 on Thursday. The company’s 50 day moving average is $3.00 and its 200 day moving average is $3.81. Geron has a 1-year low of $1.46 and a 1-year high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock has a market cap of $988.36 million, a price-to-earnings ratio of -5.11 and a beta of 0.53.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on GERN shares. Barclays reiterated an “overweight” rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a research note on Thursday. Needham & Company LLC reduced their price target on Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday. B. Riley lowered shares of Geron from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $3.50 to $2.00 in a report on Thursday. Finally, HC Wainwright lowered shares of Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.14.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.